France· FR:68552628
LYTGOBI 4 mg, comprimé pelliculé
A futibatinib product containing futibatinib, registered in France by TAIHO PHARMA NETHERLANDS (PAYS-BAS), on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Futibatinib is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EN04 (futibatinib), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 8 of them publish a price we can compare per daily dose
Futibatinib · ATC L01EN04
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of futibatinib costs, country by country.
Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.36 in France to $366.73 in Switzerland — a ×1007 gap.
- France: $0.36 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Futibatinib · price per daily dose (20 mg)
USD · FX 28 Sept 2026
- CH Switzerland$366.73
- FR France$0.36
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- FUTIBATINIB
- Manufacturer
- TAIHO PHARMA NETHERLANDS (PAYS-BAS)
- Country
- France (FR)
- ATC code
- L01EN04
- ATC class
- Futibatinib
- Defined daily dose
- 20 mg, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930276600plaquette(s) PVC polychlortrifluoroéthylène aluminium de 35 comprimé(s)EUR 2.24
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Futibatinib in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLYTGOBITaiho Pharma Netherlands B.V., Amsterdam
- SwitzerlandLytgobi 4 mg, FilmtablettenTaiho Oncology Europe GmbH
- FinlandLytgobiTaiho Pharma Netherlands B.V.
- IrelandLytgobi 4 mg film-coated tabletTaiho Pharma Netherlands B.V.
- IcelandLytgobiTaiho Pharma Netherlands B.V.
- NetherlandsLytgobi 4 mg filmomhulde tablettenTaiho Pharma Netherlands B.V.
- PolandLytgobiTaiho Pharma Netherlands B.V.
- BelgiumLytgobi 4 mgTaiho Pharma Netherlands
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d2d2bc78-9ccd-4eea-9798-532aac2a7f8d GET /v1/drugs/d2d2bc78-9ccd-4eea-9798-532aac2a7f8d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68552628",
"date_amm": "2023-07-04",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/23/1741",
"substance": "FUTIBATINIB",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about futibatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.